Trans fat labeling
This article was originally published in The Tan Sheet
Executive Summary
FDA has added an addendum to its recent guidance on requesting an extension to use existing label stock after the trans fat labeling effective date of Jan. 1, the agency said Dec. 30. Due to the "numerous requests" from industry on the guidance and the agency's "limited resources to handle all of these pending requests prior to the Jan. 1 effective date," FDA will only consider requests postmarked as of Dec. 31. In order to be considered, the requests must be for product labels that otherwise comply with FDA labeling requirements. The product also must not contain more than 0.5 g trans fat per labeled serving. The labeling guidance was released Dec. 14 (1"The Tan Sheet" Dec. 12, 2005, In Brief)...
You may also be interested in...
Trans fat labeling
"The estimate of the amount of time needed, not exceeding 12 months, to exhaust the number of existing labels for all products identified that the firm is requesting to use," is one factor CFSAN will take into account when reviewing requests for extensions on compliance with the trans fat labeling final rule, according to a 1guidance released by the Center for Food Safety & Applied Nutrition. According to the center, the guidance will publish in an upcoming issue of the Federal Register. FDA "does not object" to the use of "alternate means of compliance" such as a sticker label declaring the amount of trans fat in a product as long as the sticker "adheres to the package under intended storage conditions," the guidance states. The final rule on trans fat labeling was released in 2003 (2"The Tan Sheet" July 14, 2003, p. 7)...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.